Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reducing light sensitivity after photodynamic therapy
2011-006012-31Phase 2Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Jan 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methyl aminolevulinate in photoaging, sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: skin redness after treatment. Started Jan 2012; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
photoaging
Beyond the preview
Go deeper on 2011-006012-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006012-31.